{"id":6150,"date":"2025-03-26T15:36:25","date_gmt":"2025-03-26T12:36:25","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6150"},"modified":"2025-03-26T15:36:25","modified_gmt":"2025-03-26T12:36:25","slug":"a-new-drug-ataciguat-has-shown-promise-in-treating-aortic-stenosis-slowing-the-progression-of-aortic-stenosis-as-and-potentially-reducing-the-need-for-tavr-or-savr-procedures","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/a-new-drug-ataciguat-has-shown-promise-in-treating-aortic-stenosis-slowing-the-progression-of-aortic-stenosis-as-and-potentially-reducing-the-need-for-tavr-or-savr-procedures\/","title":{"rendered":"A new drug, ataciguat, has shown promise in Treating Aortic Stenosis &#038; slowing the progression of aortic stenosis (AS) and potentially reducing the need for TAVR or SAVR procedures."},"content":{"rendered":"<div>Key Summary: <span> <\/span>A new drug, ataciguat, has shown promise in Treating Aortic Stenosis &amp; slowing the progression of aortic stenosis (AS) and potentially reducing the need for TAVR or SAVR procedures.<\/div>\n<div><\/div>\n<div><span> \u2022 Research led by Mayo Clinic demonstrated that\u00a0 ataciguat reactivates oxidized soluble guanylate cyclase, limiting fibrocalcific aortic valve stenosis (FCAVS) progression.<\/span><\/div>\n<div><span> \u2022 Phase I clinical trial confirmed the drug is well tolerated in patients with FCAVS.<\/span><\/div>\n<div><span> \u2022 In a Phase II trial, six months of ataciguat treatment led to a ~70% reduction in aortic valve calcification progression compared to placebo.<\/span><\/div>\n<div><span> \u2022 The drug also appeared to slow valvular and ventricular dysfunction, which reflects disease progression.<\/span><\/div>\n<div><span> \u2022 Jordan Miller, PhD, emphasized that ataciguat could delay or prevent the need for valve replacement, significantly benefiting patients.<\/span><\/div>\n<div><span> \u2022 Further large-scale clinical trials and long-term follow-up are needed to confirm ataciguat\u2019s effectiveness in AS treatment.<\/span><\/div>\n<div><span> \u2022 The study was a collaboration between Mayo Clinic, NIH, University of Minnesota, and Sanofi Pharmaceuticals, with Phase III trials already in progress.<\/span><\/div>\n<div><\/div>\n<div>This discovery represents a major step in non-surgical AS treatment, with potential implications for millions of patients.<\/div>\n<div><\/div>\n<div>Reference: Circulation 24 February 2025<\/div>\n<div><a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.123.066523\" target=\"_blank\" rel=\"noopener\">https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.123.066523<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Key Summary: A new drug, ataciguat, has shown promise in Treating Aortic Stenosis &amp; slowing the progression of aortic stenosis (AS) and potentially reducing the need for TAVR or SAVR procedures. \u2022 Research led by Mayo Clinic demonstrated that\u00a0 ataciguat reactivates oxidized soluble guanylate cyclase, limiting fibrocalcific aortic valve stenosis (FCAVS) progression. \u2022 Phase I [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6150","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6150"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6150\/revisions"}],"predecessor-version":[{"id":6151,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6150\/revisions\/6151"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}